<DOC>
	<DOCNO>NCT01524445</DOCNO>
	<brief_summary>The purpose retrospective study collect information patient receive bortezomib first chemotherapy respond well , relapse afterwards treat bortezomib second time treatment-free period least 6 month . During non-interventional study ( mean drug test study ) safety effectiveness ( whether work ) bortezomib re-treatment evaluated patient multiple myeloma . Only data already mention clinical file collect . About 100 adult patient take part study</brief_summary>
	<brief_title>Retrospective Survey Re-treatment With Bortezomib</brief_title>
	<detailed_description>This international , multicenter , non-interventional , retrospective study evaluate efficacy safety bortezomib 100 adult patient diagnose multiple myeloma ( MM ) respond bortezomib first-line treatment , experience partial response well , present relapsed disease , re-treated ( second-line ) bortezomib ( least 3 cycle ) treatment-free interruption least 6 month . As non-interventional study , change current treatment patient receives require , additional treatment provide company . The decision patient take part study impact care receive . All appropriate treatment-related decision make treat physician ( ) , data available clinical practice collect . Retrospective data collect single time point patient ( data collection visit ) . Each investigator collect data patient fulfil inclusion exclusion criterion . After receive sign informed consent form ( ICF ) patient ( required local regulation ) , investigator start document retrospective data patient use electronic data capture ( eDC ) . After confirmation patient 's eligibility , patient 's last visit , patient characteristic , predefined risk factor ( available ) , MM-related data , first- second-line bortezomib-related data document Case Report Form ( CRF ) . The patient 's status re-treatment bortezomib , medical resource utilization data , well ( serious ) adverse drug reaction ( [ S ] ADRs ) collect . No blood , urine , biological sample take , additional investigation perform . current therapy patient maintain change</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Has current diagnosis/was diagnose MM secretory MM Was previously treat bortezomibcontaining chemotherapy Responded bortezomib firstline treatment Has retreat bortezomib ( least 3 cycle ) due relapse disease ( follow first bortezomib treatment ) , treatmentfree interruption least 6 month Completed bortezomib retreatment least 2 month ago Was pregnant breastfeed woman receive either firstline secondline treatment Velcade Has receive bortezomibcontaining chemotherapy first time follow first relapse later Has participate clinical trial bortezomib use secondline treatment follow relapse response Velcade firstline chemotherapy , study data publicly available time inclusion current study Has receive bortezomib firstline therapy retreat bortezomib first relapse VISTA clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Bortezomib</keyword>
	<keyword>Velcade</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>retrospective study , response rate , medical resource utilization</keyword>
</DOC>